RxDoctor Payments Data

Danette Pengilly

Gerontology · Bismarck, NDNPI 1013016989

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 21 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 11 manufacturers reported payments, led by Boehringer Ingelheim at 31.8% of the total.

$546in general payments, 2019–2025

Across 21 payments — averaging $25.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$173
  • Edwards Lifesciences$72
  • Medtronic$59
  • Novartis$54
  • Impulse Dynamics (USA) Inc.$50
  • E.r. Squibb & Sons, L.L.C.$37
  • plus $100 from 5 others

What the payments were for

  • Food & beverage$546100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

Too few gerontology providers in North Dakotato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$38,831
Medicare patients
322
Services billed
606

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban247$224,276
JardianceEmpagliflozin52$54,230
XareltoRivaroxaban26$35,691
Repatha SureclickEvolocumab14$14,767
EntrestoSacubitril/Valsartan13$11,284
Metoprolol Succinate558$9,954
Potassium Chloride230$6,872
Spiriva HandihalerTiotropium Bromide14$6,732
Rosuvastatin Calcium503$6,266
Atorvastatin Calcium430$5,280
BrilintaTicagrelor11$4,730
Losartan Potassium328$3,334
Ezetimibe134$3,240
Ranolazine ErRanolazine22$3,088
ClopidogrelClopidogrel Bisulfate204$2,872

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$16$224,276247 claims
Boehringer IngelheimJardiance$173$54,23052 claims
Johnson & JohnsonXarelto$13$35,69126 claims
NovartisEntresto$54$11,28413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few gerontology providers in North Dakotaon file to place this against a meaningful peer group, so we don't.

Other gerontology in Bismarck

See the full list for North Dakota

Where these figures come from

Is this you, or does something look wrong? →